Valganciclovir is effective prophylaxis for CMV in high risk renal transplant recipients.

被引：0
|
作者：
Baillie, GM [1 ]
Ashcraft, EE [1 ]
Taber, DJ [1 ]
Stone, SS [1 ]
Emovon, O [1 ]
Rogers, J [1 ]
Afzal, F [1 ]
Lin, A [1 ]
Rajagopalan, PR [1 ]
Baliga, PK [1 ]
Chavin, KD [1 ]
机构：
[1] Med Univ S Carolina, Div Transplant Surg, Charleston, SC 29425 USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2002年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：377A / 377A
页数：1
相关论文
共 50 条
  • [1] Valganciclovir for CMV prophylaxis in paediatric transplant recipients.
    Wiesmayr, S
    Stelzmueller, I
    Jungraithmayr, T
    Mark, W
    Larcher, C
    Margreiter, R
    Zimmerhackl, L
    Bonatti, H
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 355 - 355
  • [2] Valganciclovir as CMV prophylaxis in pediatric transplant recipients.
    Bonatti, H
    Wiesmayr, S
    Junngraithmayr, TC
    Margreiter, R
    Zimmerhackl, LB
    PEDIATRIC TRANSPLANTATION, 2005, 9 : 98 - 98
  • [3] Ganciclovir prophylaxis in CMV high-risk renal transplant recipients.
    Kletzmayr, J
    Safar, T
    Kovarik, J
    Klauser, R
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A3210 - A3210
  • [4] Risk Factors for Leukopenia with Valganciclovir Prophylaxis in CMV High Risk Cardiothoracic Transplant Recipients
    Brueckner, A. J.
    Doligalski, C. T.
    Logan, A. T.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S365 - S366
  • [5] A prospective trial of valganciclovir prophylaxis for cytomegalovirus (CMV) prevention in lung transplant recipients.
    Humar, A
    Kumar, D
    Preiksaitis, J
    Fenton, J
    Nia, S
    Jackson, K
    Chernenko, S
    Lien, D
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 270 - 270
  • [6] Ganciclovir vs. valganciclovir for CMV prophylaxis in solitary pancreas transplant recipients.
    Rea, DJ
    Kudva, YC
    Larson, TS
    Stegall, MD
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 380 - 380
  • [7] Efficacy and safety of valganciclovir in prophylaxis of cytomegalovirus disease in renal transplant recipients.
    Gabardi, S
    Powelson, J
    Baroletti, SA
    Cina, JL
    Goggins, WC
    PHARMACOTHERAPY, 2003, 23 (03): : 412 - 413
  • [8] Incidence of CMV with dual therapy prophylaxis in renal transplant recipients.
    Baillie, GM
    Ashcraft, EE
    Polito, CC
    Buchanan, EP
    Rodwell, D
    Emovon, O
    Afzal, F
    Rogers, J
    Lin, A
    Brown, E
    Baliga, PK
    Rajagopalan, PR
    Chavin, KD
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 780A - 780A
  • [9] Burden of Primary CMV Infections Remains High Despite Six Months Valganciclovir Prophylaxis in High-Risk Kidney Transplant Recipients.
    Helantera, I.
    Ortiz, F.
    Loginov, R.
    Mannonen, L.
    Lempinen, M.
    Lautenschlager, I.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 533 - 533
  • [10] Incidence of CMV Disease in High-Risk Liver Transplant Recipients on Low Dose Valganciclovir Prophylaxis
    Tischer, S.
    Park, J.
    Stuckey, L.
    Kaul, D.
    Sonnenday, C.
    Fontana, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 221 - 222
12345